'Funding Your Scientific Start-Up'


 Thursday, March 10, 2011 






Venture capital (VC) is a critical source of funding for early stage science and technology businesses.  Our panel of successful VC experts will discuss some of the key elements they look for in prospective companies, the best way to pitch ideas to potential investors, and career paths related to investing in start-ups. Venture Capital is an essential source of funding for early-stage science & technology start-ups. There will be ample time for questions from the audience. Whether you're thinking of funding your own start-up or simply want a rare insider's view, come join us to learn from our panelists' own experience.



Janice Bourque, Managing Director, Hercules Technology Growth Capital  Prior to joining Hercules, Janice recently advised and provided strategic corporate investor fundraising for Commons Capital and Oxford Bioscience Partners to create global health fund focused on innovative healthcare investments for emerging and developing countries. Previously, she was Senior Vice President and Group Head-Life Sciences for Comerica Bank where she delivered value to the industry and portfolio growth through relationship development and creative debt financing. Formerly, Janice was President/CEO of the Massachusetts Biotechnology Council (MBC). MBC was the first biotechnology association in the world and achieved national and international leadership during her tenure. She held several other senior managerial positions, including CFO/controller of Cambridge Medical Technology Corporation, senior public accountant for Coopers & Lybrand Emerging and Middle Market Group, and project manager for NASA Space Science at UNH. Janice is currently on the boards of the MIT Koch Institute for Integrative Cancer Research, the Village Bank, TBS Technologies and Board Chair for National Center for Family Homelessness. She has won numerous awards and was named one of Boston Magazine’s 100 most influential women. Janice received her MBA degree in finance and accounting and her BS degree in veterinary science from the University of New Hampshire.

Maggie Le Flore, Venture Partner, MedImmune Ventures Maggie joined MedImmune Ventures as a managing director in 2007, moving into a Venture Partner role in 2011.She was previously Head of R&D Ventures at AstraZeneca, during which time she spent two years on assignment to Advent International working with their Healthcare and Life Sciences venture capital investment team. From 2001 to 2005, Maggie was the Global Alliance Director for Global Sciences and Information at AstraZeneca, where she led an international group responsible for evaluation, negotiation and management of global technology platform collaborations. From 1985 to 2001, she held business development and scientific management positions at Hybridon, OSI Pharmaceuticals and Marion Merrell Dow Pharmaceuticals. Maggie originally trained as a biophysical chemist, earning a B.S. in Chemistry from the University of Kansas and a Ph.D. in Physical Chemistry from Indiana University. She then trained in molecular and cellular biology as a post-doctoral fellow at the National Institutes of Health.


Irena Melnikova, Director of Scouting and Partnering, Sanofi-Aventis Prior to joining sanofi, Irena was a Principal in the Life Science team of TVM Capital, a global venture capital firm. At TVM, she was involved in deal origination and new investment opportunity evaluation and actively participated in the management of TVM Capital investments in the United States. Prior to TVM Capital, she launched and produced “Future in Focus,” a series of syndicated reports for Leerink Swann and was a member of the biopharma investment banking team where she supported due diligence and opportunity assessment activities that resulted in public and private financings, as well as M&A transactions. Prior to Leerink Swann, Irena was a Research Manager at Life Science Insights, a subsidiary of IDC, the leading technology market research company. As a project leader at TransForm Pharmaceuticals (acquired by Johnson & Johnson), she was responsible for running several programs, including Engineered Tissue Constructs, funded by DARPA, and Amyloidoses. She holds a PhD in Molecular Medicine/Molecular Biology from the University of Texas and an MS with Honors in Chemical Engineering and Environmental Sciences from Russian University of Chemical Technology. Irena has published over 20 manuscripts in peer-reviewed journals and is a regular contributor to the “Analyst Couch” section of Nature Reviews in Drug Discovery magazine. She is a co-inventor on a filed patent for methods for identifying conditions affecting a cell state.

Ellen Rubin, Founder & VP Products, CloudSwitch Ellen Rubin is an experienced entrepreneur with a proven track record in founding innovative technology companies and leading strategy, market positioning and go-to-market. Prior to founding CloudSwitch, Ellen was Vice President of Marketing at Netezza (NYSE: NZ), the pioneer and global leader in data warehouse appliances that power business intelligence and analytics at over 200 enterprises worldwide. As a member of the early management team at Netezza, Ellen helped grow the company to over $125 million in revenues and a successful IPO in 2007. Ellen defined and created broad market acceptance of a new category, "data warehouse appliances," and led market strategy, product marketing, complementary technology relationships and marketing communications. Prior to Netezza, Ellen founded Manna, an Israeli and Boston-based developer of real-time personalization software. Ellen played a key role in raising over $18 million in venture financing from leading US and Israeli venture capital firms, recruiting the US-based management team and defining product and market strategy. Ellen began her career as a marketing strategy consultant at Booz, Allen & Hamilton, and holds an MBA from Harvard Business School and an undergraduate degree magna cum laude from Harvard College.



Advance Registration (by 9pm, Tuesday, March 8):
$45 for WEST Members, $65 for non-WEST members

At the Door: $10 additional.  Student Scholarship Information

Refreshments are included.



Event Location:

IBM Center for Social Software

1 Rogers Street, Cambridge, MA 02142 



(Discounted parking is available in the Galleria Mall, for walking directions, click HERE)



6:00-7:00 Registration, Networking and Refreshments

7:00-8:30 Panel Discussion

8:30-9:00 Networking and Refreshments



Preregistration ends Tuesday March 8 at 9pm.







  c4ss orange w ibm.png